- Home
- CNTX vs BAFN Comparison
CNTX vs BAFN Comparison
Compare CNTX & BAFN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTX
- BAFN
- Stock Information
- Founded
- CNTX 2015
- BAFN 1999
- Country
- CNTX United States
- BAFN United States
- Employees
- CNTX N/A
- BAFN N/A
- Industry
- CNTX Biotechnology: Pharmaceutical Preparations
- BAFN Savings Institutions
- Sector
- CNTX Health Care
- BAFN Finance
- Exchange
- CNTX Nasdaq
- BAFN Nasdaq
- Market Cap
- CNTX 60.7M
- BAFN 70.2M
- IPO Year
- CNTX 2021
- BAFN N/A
- Fundamental
- Price
- CNTX $0.84
- BAFN $14.10
- Analyst Decision
- CNTX Strong Buy
- BAFN
- Analyst Count
- CNTX 5
- BAFN 0
- Target Price
- CNTX $6.50
- BAFN N/A
- AVG Volume (30 Days)
- CNTX 257.9K
- BAFN 11.1K
- Earning Date
- CNTX 05-07-2025
- BAFN 04-24-2025
- Dividend Yield
- CNTX N/A
- BAFN 2.28%
- EPS Growth
- CNTX N/A
- BAFN 134.31
- EPS
- CNTX N/A
- BAFN 2.62
- Revenue
- CNTX N/A
- BAFN $83,769,000.00
- Revenue This Year
- CNTX N/A
- BAFN N/A
- Revenue Next Year
- CNTX N/A
- BAFN N/A
- P/E Ratio
- CNTX N/A
- BAFN $5.35
- Revenue Growth
- CNTX N/A
- BAFN 10.60
- 52 Week Low
- CNTX $0.55
- BAFN $10.40
- 52 Week High
- CNTX $2.75
- BAFN $19.75
- Technical
- Relative Strength Index (RSI)
- CNTX 56.99
- BAFN 35.32
- Support Level
- CNTX $0.80
- BAFN $13.00
- Resistance Level
- CNTX $0.89
- BAFN $14.25
- Average True Range (ATR)
- CNTX 0.11
- BAFN 1.16
- MACD
- CNTX 0.03
- BAFN -0.23
- Stochastic Oscillator
- CNTX 73.80
- BAFN 20.75
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
About BAFN BayFirst Financial Corp.
BayFirst Financial Corp is a one bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios.